TY - JOUR
T1 - A novel89zr-labeled dds device utilizing human igg variant (Scfv)
T2 - “lactosome” nanoparticle-based theranostics for pet imaging and targeted therapy
AU - Lim, Melissa Siaw Han
AU - Ohtsuki, Takashi
AU - Takenaka, Fumiaki
AU - Kobayashi, Kazuko
AU - Akehi, Masaru
AU - Uji, Hirotaka
AU - Kobuchi, Hirotsugu
AU - Sasaki, Takanori
AU - Ozeki, Eiichi
AU - Matsuura, Eiji
N1 - Funding Information:
Funding: This research was supported by a grant from the Japan Agency for Medical Research and Development, Project for Cancer Research and Therapeutic Evolution (P-DIRECT and P-CREATE).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/2
Y1 - 2021/2
N2 - “Theranostics,” a new concept of medical advances featuring a fusion of therapeutic and diagnostic systems, provides promising prospects in personalized medicine, especially cancer. The theranostics system comprises a novel89Zr-labeled drug delivery system (DDS), derived from the novel biodegradable polymeric micelle, “Lactosome” nanoparticles conjugated with specific short-ened IgG variant, and aims to successfully deliver therapeutically effective molecules, such as the apoptosis-inducing small interfering RNA (siRNA) intracellularly while offering simultaneous tumor visualization via PET imaging. A 27 kDa-human single chain variable fragment (scFv) of IgG to establish clinically applicable PET imaging and theranostics in cancer medicine was fabricated to target mesothelin (MSLN), a 40 kDa-differentiation-related cell surface glycoprotein antigen, which is frequently and highly expressed by malignant tumors. This system coupled with the cell penetrating peptide (CPP)-modified and photosensitizer (e.g., 5, 10, 15, 20-tetrakis (4-aminophenyl) por-phyrin (TPP))-loaded Lactosome particles for photochemical internalized (PCI) driven intracellular siRNA delivery and the combination of 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) offers a promising nano-theranostic-based cancer therapy via its targeted apoptosis-inducing fea-ture. This review focuses on the combined advances in nanotechnology and material sciences utilizing the “89Zr-labeled CPP and TPP-loaded Lactosome particles” and future directions based on important milestones and recent developments in this platform.
AB - “Theranostics,” a new concept of medical advances featuring a fusion of therapeutic and diagnostic systems, provides promising prospects in personalized medicine, especially cancer. The theranostics system comprises a novel89Zr-labeled drug delivery system (DDS), derived from the novel biodegradable polymeric micelle, “Lactosome” nanoparticles conjugated with specific short-ened IgG variant, and aims to successfully deliver therapeutically effective molecules, such as the apoptosis-inducing small interfering RNA (siRNA) intracellularly while offering simultaneous tumor visualization via PET imaging. A 27 kDa-human single chain variable fragment (scFv) of IgG to establish clinically applicable PET imaging and theranostics in cancer medicine was fabricated to target mesothelin (MSLN), a 40 kDa-differentiation-related cell surface glycoprotein antigen, which is frequently and highly expressed by malignant tumors. This system coupled with the cell penetrating peptide (CPP)-modified and photosensitizer (e.g., 5, 10, 15, 20-tetrakis (4-aminophenyl) por-phyrin (TPP))-loaded Lactosome particles for photochemical internalized (PCI) driven intracellular siRNA delivery and the combination of 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) offers a promising nano-theranostic-based cancer therapy via its targeted apoptosis-inducing fea-ture. This review focuses on the combined advances in nanotechnology and material sciences utilizing the “89Zr-labeled CPP and TPP-loaded Lactosome particles” and future directions based on important milestones and recent developments in this platform.
KW - ATP-binding cassette subfamily G member 2 (ABCG2)
KW - Accelerated blood clearance (ABC)
KW - Cell penetrating peptide (CPP)
KW - Drug delivery system (DDS)
KW - PET imaging
KW - Photodynamic therapy (PDT)
KW - SiRNA
KW - Single chain variable fragment of IgG (scFv)
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85102144458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102144458&partnerID=8YFLogxK
U2 - 10.3390/life11020158
DO - 10.3390/life11020158
M3 - Review article
AN - SCOPUS:85102144458
SN - 0024-3019
VL - 11
SP - 1
EP - 29
JO - Life
JF - Life
IS - 2
M1 - 158
ER -